skip to main content

COPD exacerbation prevention — USMLE Step 3 MCQ

Instant feedback + full explanation. One question, done properly.

HardInternal Medicine (chronic management)COPD exacerbation preventionUSMLE Step 3

A 68-year-old man with COPD has persistent dyspnea despite correct daily tiotropium use and pulmonary rehabilitation. FEV1 is 58% predicted, oxygen saturation is 94% at rest, and he had one outpatient exacerbation last year. Blood eosinophils are 80/µL, and he has no asthma history. Which inhaled regimen is most appropriate next?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Escalate to combined long-acting beta-agonist and muscarinic-antagonist therapy

The best answer is “Escalate to combined long-acting beta-agonist and muscarinic-antagonist therapy”. Persistent dyspnea on a single long-acting bronchodilator is an indication to escalate to LABA/LAMA dual bronchodilation. His low eosinophil count, limited exacerbation burden, and absent asthma history provide little reason to prioritize inhaled corticosteroid, which carries pneumonia risk. Chronic oral glucocorticoids are harmful, and resting saturation does not support long-term oxygen therapy.

Reference: ATS Clinical Practice Guideline: Pharmacologic Management of COPD: https://www.thoracic.org/statements/guideline-implementation-tools/pharmacologic-mgmt-of-copd.php